Supplementary Video 2-F3.mp4 (715.55 kB)
Download file

Supplementary Video 2-F3: Cytotoxic T lymphocytes targeting a conserved SARS-CoV-2 spike epitope are efficient serial killers

Download (715.55 kB)
media
posted on 17.03.2022, 13:51 by Daniel Meyer, Mohsen Fathi, Lindsey Charley, Laurence Cooper, Navin Varadarajan

Supplementary Video S2: Representative TIMING Videos displaying a killer T cell detaching from a target cell before induction of apoptosis.

Funding

NV was supported by the NIH (R01GM143243), CPRIT (RP180466), MRA Established Investigator Award (509800), NSF (1705464), CDMRP (CA160591), and Owens foundation. DDM, NV, MF, LC and LJNC have equity ownership in CellChorus. LJNC receives royalties from Bristol Myers Squibb (via City of Hope National Medical Center) and Immatics (via MD Anderson Cancer Center), holds receipts of intellectual property rights from Sangamo BioSciences, MD Anderson Cancer Center, and Ziopharm Oncology, and also has equity ownership interest in Targazyme, Ziopharm Oncology, Immatics, Secure Transfusion Services, AuraVax Therapeutics, and IterateBio. NV has equity ownership in AuraVax Therapeutics and owns intellectual property rights from UH.

History